SCHEMBL5263501

SCHEMBL5263501

O=S(=O)(Cl)NC1CCc2ccccc2N1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 3/20 0.41
SMYD3 Q9H7B4 1/20 0.40
CA1 P00915 3/20 0.39
CA2 P00918 3/20 0.39
SIRT2 Q8IXJ6 1/20 0.35
NPC1 O15118 1/20 0.35
MAPK13 O15264 1/20 0.35
MAPK12 P53778 1/20 0.35
MAPK11 Q15759 1/20 0.35
MAPK14 Q16539 1/20 0.35
MAPT P10636 2/20 0.35
GAA P10253 1/20 0.35
PYGL P06737 1/20 0.33
PYGM P11217 1/20 0.33
PSEN1 P49768 3/20 0.33
PSEN2 P49810 3/20 0.33
APH1B Q8WW43 3/20 0.33
NCSTN Q92542 3/20 0.33
APH1A Q96BI3 3/20 0.33
PSENEN Q9NZ42 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5261942 0.76 NPC1 (0.42) MTNR1ASMYD3CA1CA2NPC1
SCHEMBL28119251 0.75 SMYD3 (0.44) MTNR1ASMYD3CA1CA2NPC1
SCHEMBL20870877 0.75 PDPK1 (0.46) MTNR1ASMYD3NPC1MAPK13MAPK12
SCHEMBL1716130 0.72 SMYD3 (0.52) MTNR1ASMYD3CA1CA2MAPT
SCHEMBL6337843 0.69 CA1 (0.71) CA1CA2MAPTMEN1ALDH1A1
SCHEMBL7365470 0.69 MTNR1A (0.40) MTNR1ASMYD3CA1CA2SIRT2
SCHEMBL31634875 0.69 SMYD3 (0.43) MTNR1ASMYD3CA1CA2NPC1
SCHEMBL517885 0.69 SMYD3 (0.43) MTNR1ASMYD3CA1CA2NPC1
SCHEMBL7419730 0.69 MTNR1A (0.43) MTNR1ASMYD3CA1CA2NPC1
SCHEMBL23275075 0.69 MTNR1A (0.46) MTNR1ASMYD3CA1CA2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254882-A1 Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same CRYSTAL GENOMICS, INC. (KR) 2007-11-01 US disclosed
EP-1778654-A1 SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME Crystalgenomics, Inc. (KR) 2007-05-02 EP disclosed
WO-2006006832-A1 SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME CRYSTALGENOMICS, INC. (KR) 2006-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254882-A1 Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same SULT2A1, SPTLC2, SGMS2 MTNR1A 2107/4885SMYD3 145/4885CA1 3138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.